AlloVir, Inc. (ALVR)
NASDAQ
Market Cap
$45.35M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
531 of 951
Rank in Industry
291 of 544
Largest Insider Buys in Sector
ALVR Stock Price History Chart
ALVR Stock Performance
About AlloVir, Inc.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Insider Activity of AlloVir, Inc.
Over the last 12 months, insiders at AlloVir, Inc. have bought $0 and sold $191,820 worth of AlloVir, Inc. stock.
On average, over the past 5 years, insiders at AlloVir, Inc. have bought $36.7M and sold $13.14M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,930,870 shares for transaction amount of $10.99M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2023‑06‑27.
List of Insider Buy and Sell Transactions, AlloVir, Inc.
| 2025-01-10 | Sale | See Remarks | 979 0.0008% | $0.44 | $431 | -9.90% | ||
| 2025-01-10 | Sale | General Counsel | 409 0.0004% | $0.44 | $180 | -9.90% | ||
| 2025-01-10 | Sale | Chief Accounting Officer | 332 0.0003% | $0.44 | $146 | -9.90% | ||
| 2024-11-19 | Sale | See Remarks | 3,186 0.0026% | $0.55 | $1,748 | +1488.59% | ||
| 2024-11-19 | Sale | Chief Executive Officer | 8,706 0.0072% | $0.55 | $4,775 | +1488.59% | ||
| 2024-11-19 | Sale | General Counsel | 432 0.0004% | $0.55 | $237 | +1488.59% | ||
| 2024-11-19 | Sale | Chief Accounting Officer | 554 0.0005% | $0.55 | $304 | +1488.59% | ||
| 2024-11-05 | Sale | See Remarks | 5,136 0.0044% | $0.86 | $4,442 | -39.49% | ||
| 2024-11-05 | Sale | Chief Executive Officer | 10,609 0.0091% | $0.86 | $9,176 | -39.49% | ||
| 2024-11-05 | Sale | General Counsel | 2,272 0.002% | $0.86 | $1,965 | -39.49% | ||
| 2024-11-05 | Sale | Chief Accounting Officer | 1,655 0.0014% | $0.86 | $1,431 | -39.49% | ||
| 2024-10-22 | Sale | See Remarks | 1,882 0.0016% | $0.77 | $1,445 | +6.57% | ||
| 2024-10-22 | Sale | General Counsel | 766 0.0007% | $0.77 | $588 | +6.57% | ||
| 2024-10-22 | Sale | Chief Accounting Officer | 486 0.0004% | $0.77 | $373 | +6.57% | ||
| 2024-10-21 | Sale | See Remarks | 1,546 0.0013% | $0.78 | $1,204 | +3.61% | ||
| 2024-10-21 | Sale | Chief Executive Officer | 9,752 0.0085% | $0.78 | $7,597 | +3.61% | ||
| 2024-10-21 | Sale | General Counsel | 635 0.0006% | $0.78 | $495 | +3.61% | ||
| 2024-10-21 | Sale | Chief Accounting Officer | 479 0.0004% | $0.78 | $373 | +3.61% | ||
| 2024-10-03 | Sale | See Remarks | 940 0.0008% | $0.81 | $766 | -2.25% | ||
| 2024-10-03 | Sale | Chief Executive Officer | 1,493 0.0013% | $0.81 | $1,217 | -2.25% |
Insider Historical Profitability
3.91%
| Sinha Vikas | See Remarks | 1139915 22.6864% | $9.03 | 0 | 37 | |
| Brainard Diana | Chief Executive Officer | 723363 14.3963% | $9.03 | 1 | 34 | +5.55% |
| Miller Edward | General Counsel | 153541 3.0558% | $9.03 | 0 | 26 | |
| Hagen Brett R | Chief Accounting Officer | 68174 1.3568% | $9.03 | 0 | 46 | |
| GILEAD SCIENCES, INC. | 10 percent owner | 16635286 331.0734% | $9.03 | 1 | 0 | |
| Wilson John Robert | director | 3164954 62.9885% | $9.03 | 0 | 3 | |
| Vera Juan | director | 2339928 46.569% | $9.03 | 0 | 9 | |
| Leen Ann M. | Chief Scientific Officer | 2288154 45.5386% | $9.03 | 0 | 12 | |
| Brenner Malcolm | director | 818663 16.2929% | $9.03 | 0 | 11 | |
| Melian Agustin | Chief Medical Officer | 453529 9.0261% | $9.03 | 0 | 8 | |
| Jovan-Embiricos Morana | director | 342693 6.8202% | $9.03 | 1 | 7 | +5.55% |
| VAN BEEK JEROEN B | Chief Commercial Officer | 333726 6.6418% | $9.03 | 1 | 34 | +5.55% |
| Hallal David | director | 138153 2.7495% | $9.03 | 0 | 7 | |
| Atillasoy Ercem | See Remarks | 131372 2.6145% | $9.03 | 1 | 8 | +5.55% |
| Bornstein Jeffrey S | 40197 0.8% | $9.03 | 2 | 1 | +0.64% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Ecor1 Capital Llc | $8.53M | 9.82 | 11.29M | New | +$8.53M | 0.06 | |
| Artal Group S A | $4.98M | 5.74 | 6.6M | 0% | +$0 | 0.02 | |
| Octagon Capital Advisors LP | $3.17M | 3.65 | 4.2M | New | +$3.17M | 0.02 | |
| BlackRock | $2.56M | 2.94 | 3.39M | -3.98% | -$105,898.13 | <0.0001 | |
| Millennium Management LLC | $2.22M | 2.56 | 2.94M | -24.63% | -$725,761.69 | <0.01 | |
| The Vanguard Group | $2.21M | 2.54 | 2.92M | -0.55% | -$12,192.39 | <0.0001 | |
| Irenic Capital Management Lp | $1.95M | 2.24 | 2.58M | New | +$1.95M | 0.56 | |
| Redmile Group | $1.44M | 1.66 | 1.91M | 0% | +$0 | 0.02 | |
| Acadian Asset Management | $1.2M | 1.38 | 1.59M | +694.58% | +$1.05M | <0.01 | |
| Geode Capital Management | $961,803.00 | 1.11 | 1.27M | +1.65% | +$15,616.29 | <0.0001 | |
| State Street | $889,465.00 | 1.03 | 1.18M | +8.99% | +$73,340.01 | <0.0001 | |
| American International Group | $19.79M | 1 | 1.15M | -0.02% | -$3,721.61 | 0.07 | |
| Acuitas Investments, LLC | $739,500.00 | 0.85 | 979,600 | New | +$739,500.00 | 0.39 | |
| D. E. Shaw & Co. | $656,659.00 | 0.76 | 869,862 | +244.31% | +$465,941.77 | <0.01 | |
| Renaissance Technologies | $650,000.00 | 0.75 | 861,494 | +13.06% | +$75,094.95 | <0.01 | |
| Charles Schwab | $347,878.00 | 0.4 | 460,826 | -3.15% | -$11,328.04 | <0.0001 | |
| Northern Trust | $339,309.00 | 0.39 | 449,475 | +4.73% | +$15,322.22 | <0.0001 | |
| Marshall Wace | $273,853.00 | 0.32 | 365,136 | +12.47% | +$30,358.61 | <0.0001 | |
| Morgan Stanley | $267,029.00 | 0.31 | 353,727 | -30.98% | -$119,870.79 | <0.0001 | |
| Two Sigma | $239,942.00 | 0.28 | 317,846 | +20.14% | +$40,229.39 | <0.0001 | |
| Two Sigma Advisers LP | $225,262.00 | 0.26 | 298,400 | +202.02% | +$150,677.93 | <0.0001 | |
| Fidelity Investments | $205,210.00 | 0.24 | 271,837 | -95.22% | -$4.09M | <0.0001 | |
| Gsa Capital Partners Llp | $171,000.00 | 0.2 | 226,627 | +8.55% | +$13,465.59 | 0.01 | |
| Pennant Capital Management Llc | $162,832.00 | 0.19 | 215,700 | 0% | +$0 | 0.03 | |
| Bml Capital Management Llc | $151,330.00 | 0.17 | 200,464 | New | +$151,330.00 | 0.12 | |
| Tealwood Asset Management | $135,039.00 | 0.16 | 178,883 | New | +$135,039.00 | 0.03 | |
| Goldman Sachs | $121,156.00 | 0.14 | 160,493 | -65.56% | -$230,680.52 | <0.0001 | |
| BNY Mellon | $120,348.00 | 0.14 | 159,423 | -22.22% | -$34,386.33 | <0.0001 | |
| Citadel Advisors LLC | $110,366.00 | 0.13 | 146,200 | -39.05% | -$70,710.49 | <0.0001 | |
| Qube Research & Technologies | $81,271.00 | 0.09 | 107,658 | -45.36% | -$67,457.84 | <0.0001 | |
| T. Rowe Price | $74,000.00 | 0.09 | 97,986 | +127.42% | +$41,461.03 | <0.0001 | |
| AQR Capital | $70,779.00 | 0.08 | 93,759 | -24.63% | -$23,131.00 | <0.0001 | |
| Susquehanna International Group | $69,221.00 | 0.08 | 91,695 | +155.43% | +$42,120.67 | <0.0001 | |
| Samsara Biocapital Llc | $62,155.00 | 0.07 | 82,336 | 0% | +$0 | 0.01 | |
| Lido Advisors, LLC | $59,951.00 | 0.07 | 79,416 | 0% | +$0 | <0.0001 | |
| Deutsche Bank | $53,771.00 | 0.06 | 70,751 | +227.64% | +$37,359.49 | <0.0001 | |
| Dimensional Fund Advisors | $52,668.00 | 0.06 | 69,769 | -1.97% | -$1,056.85 | <0.0001 | |
| RhumbLine Advisers | $52,083.00 | 0.06 | 68,999 | +8.46% | +$4,061.78 | <0.0001 | |
| AllianceBernstein | $48,638.00 | 0.06 | 64,430 | 0% | +$0 | <0.0001 | |
| Verition Fund Management Llc | $48,174.00 | 0.06 | 63,815 | New | +$48,174.00 | <0.0001 | |
| Raymond James Financial Services Advisors Inc | $45,671.00 | 0.05 | 60,500 | +80.92% | +$20,427.39 | <0.0001 | |
| UBS | $41,900.00 | 0.05 | 55,496 | -8.46% | -$3,874.71 | <0.0001 | |
| Tudor Investment Corp Et Al | $37,458.00 | 0.04 | 49,620 | 0% | +$0 | <0.0001 | |
| Amundi | $33,727.00 | 0.04 | 45,448 | 0% | +$0 | <0.0001 | |
| Xtx Topco Ltd | $35,073.00 | 0.04 | 46,460 | -15.24% | -$6,307.25 | <0.01 | |
| Bank of America | $34,217.00 | 0.04 | 45,381 | -35.32% | -$18,684.72 | <0.0001 | |
| Barclays | $27,000.00 | 0.03 | 35,247 | -49.39% | -$26,351.94 | <0.0001 | |
| JPMorgan Chase | $22,786.00 | 0.03 | 30,184 | -91.73% | -$252,691.03 | <0.0001 | |
| Just Invest, LLC | $21,468.00 | 0.03 | 28,438 | +146.15% | +$12,746.58 | <0.0001 | |
| Capstone Investment Advisors | $20,571.00 | 0.02 | 27,250 | +9% | +$1,698.52 | <0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.